Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA(1c), Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy

OBJECTIVE: To examine the safety and efficacy of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, added on to pioglitazone in type 2 diabetes inadequately controlled on pioglitazone. RESEARCH DESIGN AND METHODS: Treatment-naive patients or those receiving metformin, sulfonylurea, or thiazo...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Rosenstock, Julio, Vico, Marisa, Wei, Li, Salsali, Afshin, List, James F.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Diabetes Association 2012
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3379599/
https://ncbi.nlm.nih.gov/pubmed/22446170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc11-1693
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky